Aptamers in diagnostics and treatment of viral infections

Viruses

Volumn 7, Issue 2, 2015, Pages 751-780

  Wandtke, Tomasz ^a   Woźniak, Joanna ^a   Kopiński, Piotr ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Aptamer; Ebola; H5N1; HCV; HIV; HPV; HSV; SELEX

Indexed keywords

APTAMER; DNA POLYMERASE; VIRUS DNA;

ANTIVIRAL THERAPY; DISEASE TRANSMISSION; EBOLA VIRUS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS A H5N1; NONHUMAN; NUCLEIC ACID ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SAMPLING; SARS CORONAVIRUS; VIRUS INFECTION; VIRUS REPLICATION; ANIMAL; DRUG EFFECTS; HEMORRHAGIC FEVER, EBOLA; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; VIRAL PHENOMENA AND FUNCTIONS; VIRUS DISEASES;

AVES; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS; SIMPLEXVIRUS;

ANIMALS; APTAMERS, NUCLEOTIDE; HEMORRHAGIC FEVER, EBOLA; HUMANS; SELEX APTAMER TECHNIQUE; VIRUS DISEASES; VIRUS PHYSIOLOGICAL PHENOMENA;

EID: 84923054862     PISSN: 19994915     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7020751     Document Type: Review

References (125)

1. Zhou, J.; Bobbin, M.L.; Burnett, J.C.; Rossi, J.J. Current progress of RNA aptamer-based therapeutics. Front. Genet. 2012, 3, e234.
2. Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346, 818–822.
3. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249, 505–510.
4. Pagratis, N.C.; Bell, C.; Chang, Y.F.; Jennings, S.; Fitzwater, T.; Jellinek, D.; Dang, C. Potent 2'-amino-, and 2'-fluoro-2'-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat. Biotechnol. 1997, 15, 68–73.
5. Yang, X.; Fennewald, S.; Luxon, B.A.; Aronson, J.; Herzog, N.K.; Gorenstein, D.G. Aptamers containing thymidine 3'-Ophosphorodithioates: Synthesis and binding to nuclear factor-kappaB. Bioorg. Med. Chem. Lett. 1999, 9, 3357–3362.
6. Kusser, W. Chemically modified nucleic acid aptamers for in vitro selections: Evolving evolution. J. Biotechnol. 2000, 74, 27–38.
7. Eulberg, D.; Klussmann, S. Spiegelmers: Biostable aptamers. ChemBioChem 2003, 4, 979–983.
8. Mendosa, S.D.; Bowser, M.T. In vitro evolution of functional DNA using capillary electrophoresis. J. Am. Chem. Soc. 2004, 126, 20–21.
9. Berezovski, M.; Krylov, S.N. Using nonequilibrium capillary electrophoresis of equilibrium mixtures for the determination of temperature in capillary electrophoresis. Anal. Chem. 2004, 6, 7114–7117.
10. Misono, T.S.; Kumar, P.K. Selection of RNA aptamers against human influenza virus hemagglutinin using surface plasmon resonance. Anal. Biochem. 2005, 342, 312–317.
11. Burmeister, P.E.; Lewis, S.D.; Silva, R.F.; Preiss, J.R.; Horwitz, L.R.; Pendergrast, P.S.; McCauley, T.G.; Kurz, J.C.; Epstein, D.M.; Wilson, C. Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. Chem. Biol. 2005, 12, 25–33.
12. Somasunderam, A.; Ferguson, M.R.; Rojo, D.R.; Thiviyanathan, V.; Li, X.; O’Brien, W.A.; Gorenstein, D.G. Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase. Biochemistry 2005, 44, 10388–10395.
13. Szpechciński, A.; Grzanka, A. Aptamers in clinical diagnostics. Postepy Biochem. 2006, 52, 260–270.
14. Ng, E.W.; Shima, D.T.; Calias, P.; Cunningham, E.T.; Guyer, D.R.; Adamis, A.P. Pegaptanib, a targeted anti VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 2006, 5, 123–132.
15. Sundaram, P.; Kurniawan, H.; Byrne, M.E.; Wower, J. Therapeutic RNA aptamers in clinical trials. Eur. J. Pharm. Sci. 2013, 48, 259–271.
16. Gilbert, J.C.; DeFeo-Fraulini, T.; Hutabarat, R.M.; Horvath, C.J.; Merlino, P.G.; Marsh, H.N.; Healy, J.M.; Boufakhreddine, S.; Holohan, T.V.; Schaub, R.G. First-in human evaluation of anti-von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007, 116, 2678–2686.
17. Jilma, B.; Paulinska, P.; Jilma-Stohlawetz, P.; Gilbert, J.C.; Hutabarat, R.; Knöbl, P. A randomized pilot trial of the anti von Willebrand factor aptamer ARC1779 in ptients with type 2b von Willebrand disease. Thromb Haemost. 2010, 104, 563–570.
18. Laber, D.A.; Taft, B.S.; Kloecker, G.H.; Bates, P.J.; Trent, J.O.; Miller, D.M. Extended phase I study of AS1411 in renal and non-small cell lung cancers. In Proceedings of the American Society of Clinical Oncology Annual Meeting, Atlanta, GA, USA, 2–6 June 2006; p. 13098.
19. Bai, H.; Wang, R.; Hargis, B.; Lu, H.; Li, Y. A SPR Aptasensor for detection of avian influenza virus H5N1. Sensors 2012, 12, 12506–12518.
20. Zhou, J.; Li, H.; Li, S.; Zaia, J.; Rossi, J.J. Novel dual inhibitory function aptamer–siRNA delivery system for HIV-1 therapy. Mol. Ther. 2008, 16, 1481–1489.
21. Fletcher, S.J.; Phillips, L.W.; Milligan, A.S.; Rodda, S.J. Toward specific detection of Dengue virus serotypes using a novel modular biosensor. Biosens. Bioelectron. 2010, 26, 1696–1700.
22. Negri, P.; Chen, G.; Kage, A.; Nitsche, A.; Naumann, D.; Xu, B.; Dluhy, R.A. Direct optical detection of viral nucleoprotein binding to an anti-Influenza aptamer. Anal. Chem. 2012, 84, 5501–5508.
23. Ruslinda, R.A.; Tanabe, K.; Ibori, S.; Wang, X.; Kawarada, H. Effects of diamond-FET-based RNA aptamer sensing for detection of real sample of HIV-1 Tat protein. Biosens. Bioelectron. 2013, 40, 277–282.
24. Tombelli, S.; Minunni, M.; Luzi, E.; Mascicni, M. Aptamer-based biosensors for the detection of HIV-1 Tat protein. Bioelectrochemistry 2005, 67, 135–141.
25. Liu, J.; Yang, Y.; Hu, B.; Ma, Z.; Huang, H.; Yu, Y.; Liu, S.; Lu, M.; Yang, D. Development of HBsAg-binding aptamers that bind HepG2.2.15 cells via HBV surface antigen. Virol. Sin. 2010, 25, 27–35.
26. Chen, F.; Hu, Y.; Li, D.; Chen, H.; Zhang, X. CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for Hepatitis C Virus envelope glycoprotein E2. PLOS ONE 2009, 4, e8142.
27. Toscano-Garibay, J.D.; Benitez-Hess, M.L.; Alvarez-Salas, L.M. Isolation and characterization of an RNA aptamer for the HPV-16 E7 oncoprotein. Arch. Med. Res. 2011, 42, 88–96.
28. Cho, S.J.; Woo, H.M.; Kim, K.S.; Oh, J.W.; Jeong, Y.J. Novel system for detecting SARS coronavirus nucleocapsid protein using an ssDNA aptamer. J. Biosci. Bioeng. 2011, 112, 535–540.
29. Bruno, J.G.; Carrillo, M.P.; Richarte, A.M.; Phillips, T.; Anfrews, C.; Lee, J.S. Development, screening, and analysis of DNA aptamer libraries potentially useful for diagnosis and passive immunity of arboviruses. BMC Res. Notes 2012, 5, e633.
30. Ellenbecker, M.; Sears, L.; Li, P.; Lanchy, J.M.; Lodmell, S.J. Characterization of RNA aptamers directed against the nucleocapsid protein of Rift Valley fever virus. Antiviral Res. 2012, 93, 330–339.
31. Katz, J.M. The impact of avian influenza viruses on public health. Avian Dis. 2003, 47, 914–920.
32. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO, 2003–2015. Available online: http://www.who.int/influenza/human_animal_interface/EN_GIP_20150106CumulaiveNumberH5N1cases.pdf?ua=1 (accessed on 20 January 2015).
33. Capua, I.; Cattoli, G. Prevention and control of highly pathogenic avian influenza with particular reference to H5N1. Virus Res. 2013, 178, 114–120.
34. Gopinath, S.C.; Kawasaki, K.; Kumar, P.K. Selection of RNA-aptamer against human influenza B virus. Nucleic Acids Symp. Ser. 2005, 49, 85–86.
35. Gopinath, S.C.; Misono, T.S.; Kawasaki, K.; Mizuno, T.; Imai, M.; Odagiri, T.; Kumar, P.K. An RNA aptamer that distinguishes between closely related human influenza viruses and inhibits haemagglutinin-mediated membrane fusion. J. Gen. Virol. 2006, 87, 479–487.
36. Wang, R.; Li, Y. Hydrogel based QCM aptasensor for detection of avian influenza virus. Biosens. Bioelectron. 2013, 42, 148–155.
37. Shiratori, I.; Akitomi, J.; Boltz, D.A.; Horii, K.; Furuichi, M.; Waga, I. Selection of DNA aptamers that bind to influenza A viruses with high affinity and broad subtype specificity. Biochem. Biophys. Res. Commun. 2014, 443, 37–41.
38. Park, J.H.; Jee, M.H.; Kwon, O.S.; Keum, S.J.; Jang, S.K. Infectivity of hepatitis C virus correlates with the amount of envelope protein E2: Development of a new aptamer-based assay system suitable for measuring the infectious titer of HCV. Virology 2013, 439, 13–22.
39. Labib, M.; Zamay, A.S.; Muharemagic, D.; Chechik, A.V.; Bell, J.C.; Berezovski, M.V. Aptamer-based viability impedimetric sensor for viruses. Anal. Chem. 2012, 84, 1813–1816.
40. Tang, Z.; Parekh, P.; Turner, P.; Moyer, R.W.; Tan, W. Generating aptamers for recognition of virus-infected cells. Clin. Chem. 2009, 55, 813–822.
41. Parekh, P.; Tang, Z.; Turner, P.C.; Moyer, R.W.; Tan, W. Aptamers recognize glycosylated hemagglutinin expressed on the surface of vaccinia virus-infected cells. Anal. Chem. 2010, 82, 8642–8649.
42. Graham, J.C.; Zarbl, H. Use of Cell-SELEX to generate DNA aptamers as molecular probes of HPV-associated cervical cancer cells. PLOS ONE 2012, 7, e36103.
43. Lee, S.; Kim, Y.S.; Jo, M.; Jin, M.; Lee, D.; Kim, S. Chip-based detection of hepatitis C virus using RNA aptamers that specifically bind to HCV core antigen. Biochem. Biophys. Res. Commun. 2007, 358, 47–52.
44. Leon, R.; Medina, M.; Schiff, E.R. Diagnostic tools in the evaluation of patients with viral hepatitis undergoing liver transplantation. Liver Transpl. Surg. 1998, 4, 94–103.
45. Ocadiz-Delgado, R.; Albino-Sanchez, M.E.; Garcia-Villa, E.; Aguilar-Gonzalez, M.G.; Cabello, C.; Rosete, D.; Mejia, F.; Manjarrez-Zavala, M.E.; Ondarza-Aguilera, C.; Rivera-Rosales, R.M.; et al. In situ molecular identification of the Influenza A (H1N1) 2009 Neuraminidase in patients with severe and fatal infections during a pandemic in Mexico City. BMC Infect. Dis. 2013, 13, e20.
46. Caliendo, A.M. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin. Infect. Dis. 2011, 52, 326–330.
47. Charlton, B.; Crossley, B.; Hietala, S. Conventional and future diagnostics for avian influenza. Comp. Immunol. Microbiol. Infect. Dis. 2009, 32, 341–350.
48. Luo, Q.; Huang, H.; Zou, W.; Dan, H.; Guo, X.; Zhang, A.; Yu, Z.; Chen, H.; Jin, M. An indirect sandwich ELISA for the detection of avian influenza H5 subtype viruses using anti-hemagglutinin protein monoclonal antibody. Vet. Microbiol. 2009, 137, 24–30.
49. Dhumpa, R.; Handberg, K.J.; Jørgensen, P.H.; Yi, S.; Wolff, A.; Bang, D.D. Rapid detection of avian influenza virus in chicken fecal samples by immunomagnetic capture reverse transcriptasepoly-merase chain reaction assay. Diagn. Microbiol. Infect. Dis. 2011, 69, 258–265.
50. Sidoti, F.; Rizzo, F.; Costa, C.; Astegiano, S.; Curtoni, A.; Mandola, M.L.; Cavallo, R.; Bergallo, M. Development of real time RT-PCR assays for detection of type A influenza virus and for subtyping of avian H5 and H7 hemagglutinin subtypes. Mol. Biotechnol. 2010, 44, 41–50.
51. Yang, J.; Kim, J.H.; Kim, Y. Comparison of nine different qualitative HBsAg assay kits. Korean J. Lab. Med. 2010, 30, 178–184.
52. Kim, H.; Shin, S.; Oh, E.J.; Kahng, J.; Kim, Y.; Lee, H.K.; Kwon, H.J. Comparison of the AdvanSure HBV real-time PCR test with three other HBV DNA quantification assays. Ann. Clin. Lab. Sci. 2013, 43, 230–237.
53. Muhlbacher, A.; Schennach, H.; Helden, J.; Hebell, T.; Pantaleo, G.; Bürgisser, P.; Cellerai, C.; Perm-pikul, P.; Rodriguez, M.I.; Eiras, A.; et al. Performance evaluation of a new fourth-generation HIV combination. Med. Microbiol. Immunol. 2013, 202, 77–86.
54. Saune, K.; Delaugerre, C.; Raymond, S.; Nicot, F.; Boineau, J.; Pasquier, C.; Izopet, J. Analytical sensitivity of three real-time PCR assays for measuring subtype B HIV-1 RNA. J. Clin. Virol. 2013, 57, 80–83.
55. Dunning, J.; Baillie, J.K.; Cao, B.; Hayden, F.G. Antiviral combinations for severe influenza. Lancet Infect. Dis. 2014, 14, Jeo9–1270.
56. Webster, R.G.; Govorkova, E.A. Continuing challenges in influenza. Ann. N.Y. Acad. Sci. 2014, 1323, 115–139.
57. Sahu, G.K. Potential implication of residual viremia in patients on effective antiretroviral therapy. AIDS Res. Hum. Retrovir. 2015, 31, 25–35.
58. Hui, D.S.; Memish, Z.A.; Zumla, A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr. Opin. Pulm. Med. 2014, 20, 233–241.
59. Ferir, G.; Gordts, S.C.; Schols, D. HIV-1 and its resistance to peptidic Carbohydrate-Binding Agents (CBAs): An overview. Molecules 2014, 19, 21085–21112.
60. Al-Tawfiq, J.A.; Memish, Z.A. What are our pharmacotherapeutic options for MERS-CoV? Expert Rev. Clin. Pharmacol. 2014, 7, 235–238.
61. Cortez, K.J.; Kottilil, S. Beyond interferon: Rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther. Adv. Chronic Dis. 2015, 6, 4–14.
62. Nicholson, K.G.; Wood, J.M.; Zambon, M. Influenza. Lancet 2003, 362, 1733–1745.
63. Marascio, N.; Torti, C.; Liberto, M.; Foca, A. Update on different aspects of HCV variability: Focus on NS5B polymerase. BMC Infect. Dis. 2014, 14, e1.
64. Kramvis, A. Genotypes and genetic variability of hepatitis B virus. Intervirology 2014, 57, 141–150.
65. Lazarevic, I. Clinical implications of hepatitis B virus mutations: Recent advances. World J. Gastroenterol. 2014, 20, 7653–7664.
66. Fall-Malick, F.Z.; Tchiakpé, E.; Ould Soufiane, S.; Diop-Ndiaye, H.; Mouhamedoune Baye, A.; Ould Horma Babana, A.; Touré Kane, C.; Lo, B.; Mboup, S. Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania. J. Med. Virol. 2014, 86, 404–410.
67. Holland, J.; Spindler, K.; Horodyski, F.; Grabau, E.; Nichol, S.; VandePol, S. Rapid evolution of RNA genomes. Science 1982, 215, 1577–1585.
68. Finlay, B.B.; McFadden, G. Anti-immunology: Evasion of the host immune system by bacterial and viral pathogens. Cell 2006, 124, 767–782.
69. Soriano, V.; Labarga, P.; Barreiro, P.; Fernandez-Montero, J.V.; Mendoza, C.; Esposito, I.; Benítez-Gutiérrez, L.; Peña, J.M. Drug interactions with new hepatitis C oral drugs. Expert Opin. Drug Metab. Toxicol. 2015, 2, 1–9.
70. Zornitzki, T.; Malnick, S.; Lysyy, L.; Knobler, H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J. Gastroenterol. 2015, 21, 233–239.
71. Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; Rustgi, V.K.; Shiffman, M.; Reindollar, R.; Goodman, Z.D.; Koury, K.; Ling, M.; Albrecht, J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001, 358, 958–965.
72. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2095–2128.
73. Mufhandu, H.T.; Gray, E.S.; Madiga, M.C.; Tumba, N.; Alexandre, K.B.; Khoza, T.; Wibmer, C.K.; Moore, P.L.; Morris, L.; Khati, M. UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of Human Immunodeficiency Virus type 1 Subtype C. J. Virol. 2012, 86, 4989–4999.
74. Bellecave, P.; Cazenave, C.; Rumi, J.; Staedel, C.; Cosnefroy, O.; Andreola, M.L.; Ventura, M.; Tarrago-Litvak, L.; Astier-Gin, T. Inhibition of Hepatitis C Virus (HCV) RNA polymerase by DNA aptamers: Mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells. Antimicrob. Agents Chemother. 2008, 52, 2097–2110.
75. Gopinath, S.C.; Hayashi, K.; Kumar, P.K. Aptamer that binds to the gD protein of Herpes Simplex Virus 1 and efficiently inhibits viral entry. J. Virol. 2012, 86, 6732–6744.
76. Hwang, S.Y.; Sun, H.Y.; Lee, K.H.; Oh, B.H.; Cha, Y.J.; Kim, B.H.; Yoo, J.Y. 5'-triphosphate-RNA-independent activation of RIG-I via RNA aptamer with enhanced antiviral activity. Nucleic Acids Res. 2012, 40, 2724–2733.
77. Romero-Lopez, C.; Berzal-Herranz, B.; Gomez, J.; Berzal-Herranz, A. An engineered inhibitor RNA that efficiently interferes with hepatitis C virus translation and replication. Antivir. Res. 2012, 94, 131–138.
78. Zhu, Q.; Shibata, T.; Kabashima, T.; Kai, M. Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA. Eur. J. Med. Chem. 2012, 56, 396–399.
79. Dey, A.K.; Griffiths, C.; Lea, S.M.; James, W. Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA 2005, 11, 873–884.
80. Jeon, S.H.; Kayhan, B.; Ben-Yedidia, T.; Arnon, R. A DNA aptamer prevents Influenza infection by blocking the receptor binding region of the viral hemagglutinin. J. Biol. Chem. 2004, 279, 48410–48419.
81. Choi, S.K.; Lee, C.; Lee, K.S.; Choe, S.Y.; Mo, I.P.; Seong, R.H.; Hong, S.; Jeon, S.H. DNA aptamers against the receptor binding region of hemagglutinin prevent Avian Influenza viral infection. Mol. Cells 2011, 32, 527–533.
82. Kwon, H.M.; Lee, K.H.; Han, B.W.; Han, M.R.; Kim, D.H.; Kim, D.E. An RNA aptamer that specifically binds to the glycosylated hemagglutinin of Avian Influenza virus and suppresses viral infection in cells. PLOS ONE 2014, 9, e97574.
83. Cohen, C.; Forzan, M.; Sproat, B.; Pantophlet, R.; McGowan, I.; Burton, D.; James, W. An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Virology 2008, 381, 46–54.
84. DeStefano, J.J.; Nair, G.R. Novel aptamer inhibitors of Human Immunodeficiency Virus reverse transcriptase. Oligonucleotides 2008, 18, 133–144.
85. Ramalingam, D.; Duclair, S.; Datta, S.A.; Ellington, A.; Rein, A.; Prasad, V.R. RNA aptamers directed to Human Immunodeficiency Virus type Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J. Virol. 2011, 85, 305–314.
86. Neff, C.P.; Zhou, J.; Remling, L.; Kuruvilla, J.; Zhang, J.; Li, H.; Smith, D.D.; Swiderski, P.; Rossi, J.J.; Akkina, R. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4+ T cell decline in humanized mice. Sci. Transl. Med. 2011, 3, e66ra6.
87. Zhou, J.; Neff, Ch.P.; Swiderski, P.; Li, H.; Smith, D.D.; Aboellail, T.; Remling-Mulder, L.; Akkina, R.; Rossi, J.J. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol. Ther. 2013, 21, 192–200.
88. Wheeler, L.A.; Trifonova, R.; Vrbanac, V.; Basar, R.; McKernan, S.; Xu, Z.; Seung, E.; Deruaz, M.; Dudek, T.; Einarsson, J.I.; et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J. Clin. Investig. 2011, 121, 2401–2412.
89. Biroccio, A.; Hamm, J.; Incitti, I.; Francesco, R.; Tomei, L. Selection of RNA aptamers that are specific and high-affinity ligands of the Hepatitis C Virus RNA-dependent RNA polymerase. J. Virol. 2002, 76, 3688–3696.
90. Umehara, T.; Fukuda, K.; Nishikawa, F.; Sekiya, S.; Kohara, M.; Hasegawa, T.; Nishikawa, S. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3. Nucleic Acids Symp. Ser. 2004, 48, 195–196.
91. Fukuda, K.; Umehara, T.; Sekiya, S.; Kunio, K.; Hasegawa, T.; Nishikawa, S. An RNA ligand inhibits Hepatitis C Virus NS3 protease and helicase activities. Biochem. Biophys. Res. Commun. 2004, 325, 670–675.
92. Konno, K.; Fujita, S.; Iizuka, M.; Nishikawa, S.; Hasegawa, T.; Fukuda, K. Isolation and characterization of RNA aptamers specific for the HCV minus-IRES domain I. Nucleic Acids Symp. Ser. 2008, 52, 493–494.
93. Wang, J.; Jiang, H.; Liu, F. In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection. RNA 2000, 6, 571–583.
94. Feng, H.; Beck, J.; Nassal, M.; Hu, K.H. A SELEX-screened aptamer of human Hepatitis B Virus RNA encapsidation signal suppresses viral replication. PLOS ONE 2011, 6, e27862.
95. Jang, K.J.; Lee, N.R.; Yeo, W.S.; Jeong, Y.J.; Kim, D.E. Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase. Biochem. Biophys. Res. Commun. 2008, 366, 738–744.
96. Binning, J.M.; Wang, T.; Luthra, P.; Shabman, R.S.; Borek, D.M.; Liu, G.; Xu, W.; Leung, D.W.; Basler, C.F.; Amarasinghe, G.K. Development of RNA aptamers targeting Ebola virus VP35. Biochemistry 2013, 52, 8406–8419.
97. Dey, A.K.; Khati, M.; Tang, M.; Wyatt, R.; Lea, S.M.; James, W. An aptamer that neutralizes R5 strains of Human Immunodeficiency Virus type 1 blocks gp120-CCR5 interaction. J. Virol. 2005, 79, 13806–13810.
98. Cheng, C.; Dong, J.; Yao, L.; Chen, A.; Jia, R.; Huan, L.; Guo, J.; Shu, Y.; Zhang, Z. Potent inhibition of human influenza H5N1 virus by oligonucleotides derived by SELEX. Biochem. Biophys. Res. Commun. 2008, 366, 670–674.
99. Suenaga, E.; Kumar, P.K. An aptamer that binds efficiently to the hemagglutinins of highly pathogenic avian influenza viruses (H5N1 and H7N7) and inhibits hemagglutinin-glycan interactions. Acta Biomater. 2014, 10, 1314–1323.
100. Kanai, A.; Tanabe, K.; Kohara, M. Poly(U) binding activity of hepatitis C virus NS3 protein, a putative RNA helicase. FEBS Lett. 1995, 376, 221–224.
101. Yu, X.; Gao, Y.; Xue, B.; Wang, X.; Yang, D.; Qin, Y.; Yu, R.; Liu, N.; Xu, L.; Fang, X.; Zhu, H. Inhibition of Hepatitis C Virus infection by NS5A-specific aptamer. Antivir. Res. 2014, 106, 116–124.
102. Gao, Y.; Yu, X.; Xue, B.; Zhou, F.; Wang, X.; Yang, D.; Liu, N.; Xu, L.; Fang, X.; Zhu, H. Inhibition of Hepatitis C Virus infection by DNA aptamer against NS2 protein. PLOS ONE 2014, 9, e90333.
103. Kao, R.Y.; Tsui, W.H.; Lee, T.S.; Tanner, J.A.; Watt, R.M.; Huang, J.D.; Hu, L.; Chen, G.; Chen, Z.; Zhang, L.; et al. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem. Biol. 2004, 11, 1293–1299.
104. Kim, S.J.; Kim, M.Y.; Lee, J.H.; You, J.C.; Jeong, S. Selection and stabilization of the RNA aptamers against the Human Immunodeficiency Virus type-1 nucleocapsid protein. Biochem. Biophys. Res. Commun. 2002, 291, 925–931.
105. Konno, K.; Iizuka, M.; Fujita, S.; Nishikawa, S.; Hasegawa, T.; Fukuda, K. An RNA aptamer containing two binding sites against the HCV minus-IRES domain I. Nucleosides Nucleotides Nucleic Acids 2011, 30, 185–202.
106. Kikuchi, K.; Umehara, T.; Fukuda, K.; Hwang, J.; Kuno, A.; Hasegawa, T.; Nishikawa, S. RNA aptamers targeted to domain II of Hepatitis C Virus IRES that bind to its apical loop region. J. Biochem. 2003, 133, 263–270.
107. Kikuchi, K.; Umehara, T.; Fukuda, K.; Kuno, A.; Hasegawa, T.; Nishikawa, S. A Hepatitis C Virus (HCV) internal ribosome entry site (IRES) domain III-IV targeted aptamer inhibits translation by binding to an apical loop of domain IIId. Nucleic Acids Res. 2005, 33, 683–692.
108. Kikuchi, K.; Umehara, T.; Nishikawa, F.; Fukuda, K.; Hasegawa, T.; Nishikawa, S. Increased inhibitory ability of conjugated RNA aptamers against the HCV IRES. Biochem. Biophys. Res. Commun. 2009, 386, 118–123.
109. Srisawat, C.; Engelke, D.R. Selection of RNA aptamers that bind HIV-1 LTR DNA duplexes: Strand invaders. Nucleic Acids Res. 2010, 38, 8306–8315.
110. Zhou, J.; Swiderski, P.; Li, H.; Zhang, J.; Neff, C.P.; Akkina, R.; Rossi, J.J. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 2009, 37, 3094–3109.
111. Huang, Z.; Wang, X.; Gao, G. Analyses of SELEX-derived ZAP-binding RNA aptamers suggest that the binding specificity is determined by both structure and sequence of the RNA. Protein Cell 2010, 1, 752–729.
112. Bai, J.; Banda, N.; Lee, N.S.; Rossi, J.; Akkina R. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. Mol. Ther. 2002, 6, 770–782.
113. Banerjea, A.; Li, M.J.; Remling, L.; Rossi, J.; Akkina, R. Lentiviral transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages. AIDS Res. Ther. 2004, 1, e2.
114. Hacein-Bey-Abina, S.; Garrigue, A.; Wang, G.P.; Soulier, J.; Lim, A.; Morillon, E.; Clappier, E.; Caccavelli, L.; Delabesse, E.; Beldjord, K.; et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Investig. 2008, 118, 3132–3142.
115. Zhou, J.; Li, H.; Zhang, J.; Swiderski, P.; Rossi, J. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. J. Vis. Exp. 2011, 52, e2954.
116. Griffin, L.C.; Tidmarsh, G.F.; Bock, L.C.; Toole, J.J.; Leung, L.L. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracor-poreal circuits. Blood 1993, 81, 3271–3276.
117. Beigelman, L.; Matulic-Adamic, J.; Haeberli, P.; Usman, N.; Dong, B.; Silverman, R.H.; Khamnei, S.; Torrence, P.F. Synthesis and biological activities of a phosphorodithioate analog of 2',5' oligoadenylate. Nucleic Acids Res. 1995, 23, 3989–3994.
118. Kawaguchi, T.; Asakawa, H.; Tashiro, Y.; Juni, K.; Sueishi, T. Stability, specific binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5-terminal with poly(ethylene glycol). Biol. Pharm. Bull. 1995, 18, 474–476.
119. Healy, J.M.; Lewis, S.D.; Kurz, M.; Boomer, R.M.; Thompson, K.M.; Wilson, C.; McCauley, T.G. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res. 2004, 21, 2234–2246.
120. Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.; Constien, R.; Donoghue, M.; Elbashir, S.; Geick, A.; Hadwiger, P.; Harborth, J.; et al. Therapeutic silencing of an endogenous gene by systemic admin-istration of modified siRNAs. Nature 2004, 432, 173–178.
121. Rusconi, C.P.; Roberts, J.D.; Pitoc, G.A.; Nimjee, S.M.; White, R.R.; Quick, G.; Scardino, E.; Fay, W.P.; Sullenger, B.A. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat. Bio-Tech. 2004, 22, 1423–1428.
122. Verhoef, J.J.; Carpenter, J.F.; Anchordoquy, T.J.; Schellekens, H. Potential induction of anti-PEG anti-bodies and complement activation toward PEGylated therapeutics. Drug Discov. Today 2014, 19, 1945–1952.
123. Ishida, T.; Kiwada, H. Anti-polyethyleneglycol antibody response to PEGylated substances. Biol. Pharm. Bull. 2013, 36, 889–991.
124. Armstrong, J.K.; Hempel, G.; Koling, S.; Chan, L.S.; Fisher, T.; Meiselman, H.J.; Garratty, G. Anti-body against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110, 103–111.
125. Bouchard, P.R.; Hutabarat, R.M.; Thompson, K.M. Discovery and development of therapeutic aptamers. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 237–257.